Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repurposing CRISPR/Cas9 for in situ functional assays.

Genes & development - 1 Dec 2013

Malina Abba, Mills John R, Cencic Regina, Yan Yifei, Fraser James, Schippers Laura M, Paquet Marilène, Dostie Josée, Pelletier Jerry

Abstract excerpt

RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle target, we readapted the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated 9)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, p53
Share to Genetic Techniques
Share to Genome

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphoma

Share to Mice, Inbred C57BL

Share to Mutation

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 24298059
DOI: 10.1101/gad.227132.113
PMCID: PMC3861673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repurposing CRISPR/Cas9 for in situ functional assays.PMID 24298059Read ↗

Using CRISPR-Cas9 to Dissect Cancer Mutations in Cell Lines.Semantic proximity Read ↗

Engineering CRISPR/Cas9 therapeutics for cancer precision medicineSemantic proximity Read ↗

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.Semantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Cas9 activates the p53 pathway and selects for p53-inactivating mutations.Semantic proximity Read ↗

Rapid generation of homozygous fluorescent knock-in human cells using CRISPR/Cas9 genome editing and validation by automated imaging and digital PCR screeningSemantic proximity Read ↗

Engineering Mutation Clones in Mammalian Cells with CRISPR/Cas9.Semantic proximity Read ↗

Integrated computational and experimental identification of <i>p53, KRAS</i> and <i>VHL</i> mutant selection associated with CRISPR-Cas9 editingSemantic proximity Read ↗

CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies.Semantic proximity Read ↗

Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells.Semantic proximity Read ↗

CRISPR/Cas9 and cancer targets: future possibilities and present challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.